<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND AND OBJECTIVE: The efficacy of standard chemotherapy regimen on aggressive non-Hodgkin's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (NHL) of certain pathologic types is unsatisfied </plain></SENT>
<SENT sid="1" pm="."><plain>This study was to evaluate the safety and efficacy of modified Hyper-CVAD regimen on Chinese patients with aggressive NHL </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: Clinical records of 31 NHL patients who received modified Hyper-CVAD regimen in <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">Cancer</z:e> Hospital of Chinese Academy of Medical Sciences from June 2004 to June 2008 were analyzed in terms of toxicity and response </plain></SENT>
<SENT sid="3" pm="."><plain>RESULTS: The 31 patients totally received 91 cycles of regimen A and 41 cycles of regimen B with a median of 4 cycles (ranged 1-7 cycles) </plain></SENT>
<SENT sid="4" pm="."><plain>The major toxicity was myelosuppresion: the occurrence rates of <z:hpo ids='HP_0001875'>neutropenia</z:hpo> of grades III-IV, <z:hpo ids='HP_0001873'>thrombocytopenia</z:hpo> and febrile <z:hpo ids='HP_0001875'>neutropenia</z:hpo> were 49.5%, 3.3% and 12.1% during treatment of regimen A, and were 80.5%, 82.9% and 46.3% during treatment of regimen B </plain></SENT>
<SENT sid="5" pm="."><plain>No treatment-related <z:hpo ids='HP_0011420'>death</z:hpo> was observed </plain></SENT>
<SENT sid="6" pm="."><plain>The responses were assessable in 26 patients </plain></SENT>
<SENT sid="7" pm="."><plain>The total response rate was 80.8%, and 12 patients achieved complete response (46.2%) </plain></SENT>
<SENT sid="8" pm="."><plain>CONCLUSION: Modified Hyper-CVAD regimen is a promising regimen for the patients with intermediate and high grade NHL </plain></SENT>
</text></document>